Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310544 · ClinicalTrials.gov registry record · Phase 2
Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT00310544 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 73 participants.
The verdict
NCT00310544, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle.
Interventions
- DRUG Magnevist (Gadopentetate dimeglumine, BAY86-4882)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00310544
The ClinicalTrials.gov registry entry for NCT00310544 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Magnevist (Gadopentetate dimeglumine, BAY86-4882) is the first listed.
NCT00310544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00310544 about?
NCT00310544 is a clinical study titled "Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction". The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle.
What is the current status of trial NCT00310544?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2006-03. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00310544?
The interventions under investigation include: Magnevist (Gadopentetate dimeglumine, BAY86-4882) (DRUG).
Who is sponsoring clinical trial NCT00310544?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.